Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs

GJ Kontoghiorghes - International Journal of Molecular Sciences, 2023 - mdpi.com
The design of clinical protocols and the selection of drugs with appropriate posology are
critical parameters for therapeutic outcomes. Optimal therapeutic protocols could ideally be …

Targeting receptor tyrosine kinases as a novel strategy for the treatment of triple-negative breast cancer

SK Jaradat, NM Ayoub, AH Al Sharie… - Technology in Cancer …, 2024 - journals.sagepub.com
Triple-negative breast cancer (TNBC) comprises a group of aggressive and heterogeneous
breast carcinoma. Chemotherapy is the mainstay for the treatment of triple-negative tumors …

In silico design and cell-based evaluation of two dual anti breast cancer compounds targeting Bcl-2 and GPER

LA Morelos-Garnica, S Guzmán-Velázquez… - Scientific Reports, 2023 - nature.com
According to WHO statistics, breast cancer (BC) disease represents about 2.3 million
diagnosed and 685,000 deaths globally. Regarding histological classification of BC, the …

The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8+ T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR …

M Huang, X Yu, Q Wang, Z Jiang, X Li, W Chen… - Cell Communication and …, 2024 - Springer
Abstract Objective The CD155/TIGIT axis has attracted considerable interest as an emerging
immune checkpoint with potential applications in cancer immunotherapy. Our research …

GOLPH3 Participates in Mitochondrial Fission and Is Necessary to Sustain Bioenergetic Function in MDA-MB-231 Breast Cancer Cells

CM Polanco, VA Cavieres, AJ Galarza, C Jara… - Cells, 2024 - mdpi.com
In this study, we investigated the inter-organelle communication between the Golgi
apparatus (GA) and mitochondria. Previous observations suggest that GA-derived vesicles …

[HTML][HTML] Acidic/hypoxia dual-alleviated nanoregulators for enhanced treatment of tumor chemo-immunotherapy

X Guo, X Chen, J Ding, F Zhang, S Chen, X Hu… - Asian Journal of …, 2024 - Elsevier
Chemotherapy plays a crucial role in triple-negative breast cancer (TNBC) treatment as it not
only directly kills cancer cells but also induces immunogenic cell death. However, the …

FEN1 Inhibition as a Potential Novel Targeted Therapy against Breast Cancer and the Prognostic Relevance of FEN1

J Berfelde, LS Hildebrand, L Kuhlmann… - International Journal of …, 2024 - mdpi.com
To improve breast cancer treatment and to enable new strategies for therapeutic resistance,
therapeutic targets are constantly being studied. Potential targets are proteins of DNA repair …

Targeting overexpressed surface proteins: A new strategy to manage the recalcitrant triple-negative breast cancer

A Raj, K Dua, V Kamath, AT Alex - European Journal of Pharmacology, 2024 - Elsevier
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous cancer that lacks
all three molecular markers, Estrogen, Progesterone, and Human Epidermal Growth Factor …

[HTML][HTML] Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies

N Xiong, H Wu, Z Yu - Frontiers in Oncology, 2024 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) poses significant challenges in oncology due to its
aggressive nature, limited treatment options, and poorer prognosis compared to other breast …

Employing Steered MD Simulations for Effective Virtual Screening: Active Pharmacophore Search by Dynamic Corrections to target MKK3-MYC Interactions

ME Ulug, S Ikram, E Sayyah, S Durdagi - bioRxiv, 2024 - biorxiv.org
The intricate relationship between mitogen-activated protein kinase 3 (MKK3) and MYC
proto-oncogene protein (MYC) activation holds deep implications for the progression of …